Cancer treatment response may be affected by gut bacteria

Conclusion This early-stage study gives us some insights into factors that might influence people's responses to a specific type of cancer treatment (immunotherapy with monoclonal antibodies). The findings are of interest, but don't have any immediate implications for cancer treatment. We don't know what the conditions that required antibiotic treatment were and whether these could have affected the response to immunotherapy. We don't know whether the antibiotics themselves influenced how well the immunotherapy worked, or whether it was their effect on gut bacteria. We also don't know whether having high levels of particular bacteria improves people's responses to immunotherapy, or whether the immunotherapy somehow influences the levels of specific bacteria. It's unclear whether the findings are more relevant to certain cancers or specific immunotherapies or antibiotic types, or if they're influenced by other patient characteristics. Further research first needs to clarify whether the gut bacteria directly influences people's responses to immunotherapy, and exactly how this happens. The next step would be to investigate whether treatment to change the gut bacteria could improve people's responses to cancer treatment. Overall, it's likely to be some time before we see whether this early study eventually leads to any changes in the way immunotherapy is given. These findings shouldn't cause any concern for people with cancer who need to take antibiotics. The risk of not ta...
Source: NHS News Feed - Category: Consumer Health News Tags: Cancer Source Type: news

Related Links:

Authors: Lee HJ, Han YM, An JM, Kang EA, Park YJ, Cha JY, Hahm KB Abstract INTRODUCTION: Although inflammation is defensive and healing process that maintains organ homeostasis, unresolved inflammation can lead to diseases. Polyunsaturated fatty acids (PUFAs), especially n-6 PUFAs abundant in Western diet, are precursors of pro-inflammatory mediators, whereas n-3 PUFAs possess anti-inflammatory properties. Therefore, interest in the cancer-preventive effect of n-3 PUFAs is increasing. Areas covered: We have observed significant reductions of gastrointestinal (GI) tumorigenesis in the Fat-1 transgenic mouse as evide...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Authors: Spallanzani A, Orsi G, Andrikou K, Gelsomino F, Rimini M, Riggi L, Cascinu S Abstract INTRODUCTION: Since 2007 Sorafenib has represented the only approved drug for first-line treatment of advanced hepatocellular carcinoma (HCC). Lenvatinib, an orally active inhibitor of multiple receptor tyrosine kinases (VEGFR 1-3, FGFR 1-4, PDGFRa, RET and KIT), showed preclinical and clinical activity in the treatment of solid tumours, including HCC. Areas covered: In this review we summarize the current therapeutic paradigm for the systemic treatment of advanced HCC, focusing on Lenvatinib pre-clinical and clinical dev...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
Authors: Jones RL, Le Cesne A, Ibrahim T, Garcia Del Muro X, Menge F Abstract INTRODUCTION: Health-related quality of life (HRQoL) is a patient-reported outcome that addresses patients' perceptions of symptoms across physical, emotional, cognitive and social domains. As HRQoL is currently rarely measured outside clinical trials in oncology, it must be inferred from patients' everyday performance during treatment. To gain insight into the HRQoL of advanced STS patients receiving palliative treatment in clinical practice, three case studies of patients treated with trabectedin are examined. Areas covered: The patient...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
was established in 2004 and consents patients in Wales, UK with a known or suspected cancer diagnosis to donate biosamples for future research. The resource is open access to all researchers working in cancer research, regardless of geographic location or employment sector. To December 2017, just over 13,500 patients have donated samples across a variety of tumour types. Tumour and adjacent normal tissue and blood samples are routinely collected, stored and processed to standardised protocols. Bespoke collections for unique samples such as urine or ascites are also available. Pathology data, clinical data including treatm...
Source: Open Journal of Bioresources - Category: Biotechnology Source Type: research
Publication date: Available online 17 September 2018Source: Journal of Molecular Graphics and ModellingAuthor(s): Ria Biswas, Nilkanta Chowdhury, Ranjita Mukherjee, Angshuman BagchiAbstractThe interaction of the proteins, tumor necrosis factor receptor-associated factor6 (TRAF6) and Basigin (CD147), is known to be associated with the over-expression of matrix metalloproteinases (MMPs) in melanoma cells. MMPs are known to be responsible for melanoma metastasis. Hence, TRAF6-Basigin complex can act as a potential therapeutic target. In previous studies, amino acid residues Lys340, Lys 384, Glu417 and Glu511 of TRAF6 were ide...
Source: Journal of Molecular Graphics and Modelling - Category: Molecular Biology Source Type: research
Authors: Czemerska M, Robak T, Wierzbowska A Abstract INTRODUCTION: Acute myeloid leukemia (AML) remains a poor prognosis hematological malignancy. The introduction of aggressive chemotherapy with allogeneic stem cell transplantation has resulted in improved clinical outcomes in younger patients. However, the treatment results in unfit elderly AML population remain disappointing. New strategies should be introduced to improve the prognosis in this group of patients. Areas covered: This review presents and discusses the mechanism of action, safety and efficacy of sapacitabine in AML patients. Expert opinion: Sapacit...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Samples LS, Graf SA Abstract Introduction Chronic lymphocytic leukemia (CLL) is a common hematologic malignancy with a highly variable clinical course. Frontline treatments include cytotoxic chemotherapies, immunotherapies, and small molecule inhibitors. Clinical and molecular factors guide treatment initiation and selection. Over the last decade, refinement of CLL risk stratification tools and growth of the arsenal of effective therapeutics have profoundly improved outcomes. These advances have concurrently increased the complexity of managing the early phases of treatment. Areas Covered This review descr...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Campione E, Ventura A, Diluvio L, Mazzeo M, Mazzilli S, Garofalo V, Di Prete M, Bianchi L Abstract INTRODUCTION: Actinic keratosis (AK) is considered as a superficial squamous cell carcinoma (SCC). A central role in the pathogenesis is played by chronic sun exposure. UVB causes direct damage to DNA, producing pyrimidine dimers, and suppressing the protective role of p53. The stepwise progression of AK, with an increased expression of anti-apoptotic Bcl-2, favors the progression to SCC. Moreover, the dermal response characterized by inflammation and mediated by prostaglandins is a critical component of tumo...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Authors: Daniels LM, Kufel WD Abstract INTRODUCTION: Clostridium difficile infection (CDI) has become a significant healthcare-associated infection and is strongly associated with antibiotic use. Practice guidelines have recently been revised incorporating updated recommendations for diagnosis, treatment, and prevention. Areas Covered: This review discusses updated aspects of CDI management. New and emerging pharmacologic options for treatment and prevention are reviewed. Expert opinion: Metronidazole is associated with lower rates of treatment success compared to vancomycin and should no longer be used as primary ...
Source: Expert Opinion on Pharmacotherapy - Category: Drugs & Pharmacology Tags: Expert Opin Pharmacother Source Type: research
Publication date: 20 December 2018Source: Sensors and Actuators B: Chemical, Volume 277Author(s): Xiangge Tian, Zhenhao Tian, Yan Wang, Jie Hou, Lei Feng, Liang Song, Jingnan Cui, Xiaokui Huo, Xinyu Zhao, Dayong Zhou, Chao Wang, Chengpeng Sun, Jing Ning, Xiaochi MaAbstractCisplatin is a widely used anti-cancer drug in clinic, while many cancer cells gradually exhibited serious cisplatin resistance recently, which resulted in reducing its clinical effects. Glutathione transferases (GSTs) as an extensive expressed metabolic enzyme in human, plays a significant role in the metabolism of cisplatin. Thus, sensitively and accura...
Source: Sensors and Actuators B: Chemical - Category: Chemistry Source Type: research
More News: Bladder Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Carcinoma | Epithelial Cancer | France Health | Grants | Health | Immunotherapy | Kidney Cancer | Kidney Transplant | Kidney Transplantation | Laboratory Medicine | Lung Cancer | Lung Transplant | Melanoma | Renal Cell Carcinoma | Sarcomas | Science | Skin | Skin Cancer | Study | Sweden Health | Transplant Surgery | Transplants | Urology & Nephrology